Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
I bought shares here two years ago and I hold with great confidence. The gains over this time have been consistent, but momentum changed last year and has built substantially over recent months and as the move to the new site, with production and demand build which it will this company will go onto great things, as a few others in this sector will too.
I only check the share price every few days as my holding here will grow and grow. AS the company turns to profits and revenue builds this should really go forward.
I wish investors well.
Share hunter you might do better on Twitter if you want to build awareness as you look like a voice in the wilderness here ;-) This is a company being bought into by larger share holders who do little reading on LSE. Good luck with your monologue.
Cheers, Rich
This company is not about individuals it is about the company and the impact it will have on peoples lives. As many here will have I have seen what cancer does to grand parents and my wife. Anything that can be produced to help diagnose and treat cancers without side effects and improve quality of life, I 100 % support. I have multiple investments across companies working in this field and I really like this one.
The presentation on Monday really encouraged me and the realisation that the FDA approval is so close encouraged me to take a larger holding and that I trust many who are here an invested would agree is a solid decision.
What ever the final value of the company becomes we will wait and see. But I would imagine it will be very strong as it solves some huge issues. If the FDA give Parsortix there blessing then I am sure we will see great success here both in terms of what it will bring to those suffering and a great return for investors.
I wish new investors the very best here and I am here to stay as this is now from what I can see a very good long term investment. My wife who has made incredible progress was keen to invest here too.
Cheers, Rich
I see you and RD have decided yet again to post defamatory remarks again about me.
These two post constant unfounded accusations of which they have no justification or cause. They have not meet me or know anything about my investment trades. They are cyber bullies and they have been called out many times.
I will not get drawn into their remarks again on this board. But if they continue I will report them to Admin.
This company is leading a new technology in cancer detection in the body using blood. Detecting Circulating Tumour Cells
Circulating Tumor Cells and the Parsortix® solution:
Solid tumor cancers, such as breast cancer and prostate cancer, shed cancer cells into the patient’s blood stream.
These are cells are known as Circulating Tumor Cells (CTCs). CTCs are very rare, perhaps representing a single cell in one billion blood cells, and are thus very difficult to isolate. They are, however, extremely valuable cells due to several defining features:
They contain information on the type of disease – which has the potential to inform on “personalized” care decisions and targeted drug therapies
Their presence and quantity has been shown to be indicative of patient prognosis
They are very likely to be the route by which primary (localised) tumors spread around the body so resulting in metastatic disease.
The Parsortix® system from ANGLE is able to capture and harvest CTCs from patient blood. This means that a simple peripheral blood test could be used to provide crucial medical information regarding the fluctuating status of a patient’s disease.
It is widely agreed that such a “liquid biopsy” would have a profound impact in understanding the patient’s current cancer status as well as ensuring the optimum treatment is deployed for that individual patient at that particular time.
Market Size
ANGLE’s ultimate objective is the widespread adoption of the Parsortix® system into scholarly institutions and treatment centers which specialize in the diagnosis and treatment of cancer patients. According to the World Health Organization, there were an estimated 14 million new cancer cases worldwide in 2012, a marked rise on the 12.7 million cases in 2008. In 2012, there were an estimated 32.6 million people living with cancer. (Source: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx)
The incidence of cancer continues to grow as a result of demographic, lifestyle and environmental factors and it is estimated that one in three people in the UK will get cancer during their lifetime.
There are a wide range of potential applications for harvested CTCs including diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness, and remission monitoring. We estimate that this represents a potential global market for ANGLE’s Parsortix® system worth in excess of £8 billion per annum.
ANGLE’s major focus is on the cancer market. There is also a substantial market available in the field of non-invasive fetal diagnostics, which involves harvesting fetal cells from the pregnant mother and analysing for Down’s Syndrome and many other chromosomal and genetic conditions through a simple blood test.
The presentation which you need to watch: https://youtu.be/dmihuELlhDM
The Parsortix® FDA approval coming Q2 2021 which will unlock the opportunity into a 100 billion US$ market
You may all be very interested in this new YouTube presentation on Bitcoin.
Enjoy https://youtu.be/OYcowXPgzUs
Cheers, Rich
Sorry that was a typo, I know it is million $. Sorry that mistake was not in anyway intentional!
Researcher1 - think your are also in the right direction. I am looking at YR23 at earliest for the long term Mcap.
A buyout would always be a strong possibility as the companies liquid biopsy products are seen to be the new market disrupter. A billion dollar buyout would be peanuts to some of the large pharma companies for a highly lucrative product. Pair this up with some of the inbound targeted cancer treatments from many biotech and genomic opportunities and you could see more people getting fast treatments and cure's within 10 years for many cancers which today cause people total devastation.
Cheers, Rich
I have looked at Cowen to start with. Listed on the NADAQ. 26 million shares - Market cap of 754 billion with a PE of 6.8. But they are just one player in one sector. You have to look at the US, Europe, Asia and even into China. The opportunities are global. This product is not like any of the existing liquid biopsy products. Just gives you a flavour of the opportunity.
Right now we would be excited to see 500 to 600 million market cap by year end, which is possible! I am looking ahead as this helps decide what amount to invest at these pre-FDA approval moments. Early investors always get the best returns.
Hope this helps.
Cheers, Rich
Phantom, this is based on a potential market cap of around ÂŁ5 billion and the second figure of ÂŁ10 billion. Given the size of the market and the figures given in the presentation they are numbers that really could be reached! Especially with a Nasdaq listing and the biggest target market will be the US. Mind you the global market for this product will be much much higher!
Just to keep it simple.
PWC will advise the business an all accounting maters both for the UK and internationally and their help will be invaluable on international matters with respect to export, tax etc.
They are not brokers so don't expect any SP productions from them this is the duty of the brokers. It is also the duty of the brokers to introduce new institutional investors and fund managers to the opportunities here.
Given the presentation from yesterday even an armature PI can clearly see this company is about to present to the world a product which every oncologist (cancer consultant) in the world will want in there clinic to be able to diagnose quickly not only cancer cells in the blood but to ensure that any possible secondary cancers are picked up before that have chance to do any further damage. Secondary cancer often unfortunately today goes with diagnosis till it is too late. Considering nearly 1 in 3 people are effected by cancer the investment case for a product which has a market opportunity per year of 100 billion US dollars is about as compelling as an investment can get when shares are only 60p each. By 2023 they will likely be more than ÂŁ23 each and if Angle PLC get the full backing of Pharmaceutical companies around the world then the share price could be over ÂŁ46 per share (assuming no dilution of the current share total) with joint listing around the world.
The detail is clearly stated here: https://angleplc.com/wp-content/uploads/ANGLE-Presentation-to-Biotech-Showcase-jan21-PDF.pdf
As I have said a compelling investment case! That FDA approval should be in place by the end of June this year.
Cheers, Rich
Presentation - https://youtu.be/o2iqDj_XYgw
In this interview David Wilson states at approximately 17 minutes in that ultimately the whole of the worlds population needs to be test ing regularly! Back in June last year a regular poster on here criticised me for suggesting such a thing! But that is what is needed. Clearly the current situation as David Wilson has pointed out that there is not enough capacity anytime soon to get anywhere near this requirement. I pointed out a few months ago the number of moulding machines and the tooling capacity requirements for production just for the UK would need around 70 moulding machines to produce the holders. Here lies the issue. These tools and the high production levels need quality tooling that is expensive and lead-times are long. But once these are in place the opportunity to produce millions of LFD per month would be possible.
You can be sure that the procurement teams for all suppliers will have been working flat out to deliver the parts as quickly as they can. I have come across projects which are producing for mass testing and the numbers are in the 100's millions per month! So something is going to happen.
For me the interesting point of this presentation is it is David Wilson presenting this on behalf of the LFD manufactures, not BBI, not Abingdon Health, not Omega. So I see this as a positive step.
This was released on the 30th December 2020.
Considering the interest from the market and here not many people have watched this!
Expect news soon!
Cheers, Rich
Following FDA approval, and maybe before, I would expect to see the company announce and joint listing on a US market and they may chose that moment to move from AIM to the main market.
Given the way the companies market opportunity is destined to go post FDA approval, you would expect to see a very large market uptake here.
Short term market opportunity is going to be a growing percentage of US $5 billion, but long term a percentage of US $100 billion after 2023. Revenue percentages on 10% of those market opportunities is huge.
Very exciting.
Yes sometimes you look at the market and the impact of the solutions which this companies in the biotech space are bring to the market and you have to pinch yourself that you have had the benefit of finding such a company. I have to say when I looked at the numbers and worked some valuation potentials on Angle Pharma, the numbers are eye watering. So I decided not to post what I thought. I am still not going to. Let's see what happens, but I am going to double my holding here! I don't want all those US investors getting all the benefit!
Not wanting to teach investors how to suck eggs but, use your investment ISA's or SIPPS for these investments!
Cheers, Rich
Thanks for reaching out MissBMW! It will!. Most of my research in shared on Twitter today. I was once attached to LSE, but investments are global today. There are some incredible opportunities across this sector.
Cheers, Rich
What an opportunity!
I already have a very good holding here and expected a strong presentation so added another 10,000 shares today. This company remains somewhat under the radar. But there will come a moment when it really does get going very quickly. A market cap of ÂŁ117m is very low considering the opportunity here and the multiple solutions for cancer diagnosis and evermore so the ability it gives oncologists in the lab to test if the treatment they would like to use is actually going to work. This will save so much time, reduce unnecessary side effects and ensure people get the right treatment and this will save lo=ives and the medical centres around the work billions. There is something incredible about this simple but mega effective solution and to me that makes it very valuable. I would not be surprised post FDA approval if this doesn't fly past a ÂŁ1 billion valuation within 18 months.
Great investment and an amazing solution to a huge issue, accurate diagnosis.
I wish all investors all the very best and keep safe over this difficult days.
Cheers, Rich
My bitcoin holding - not ARB is still up 99.51% from a month ago! Drip feed those buys and prediction for year end is $100,000 plus.
ARB will be a long term riser on the back of this.
If you want to do some real research see what Cathie Wood has today about Bitcoin, then research Raoul Pal and then Max Kieser - https://www.youtube.com/watch?v=PmEtVoF63IM&t=4s
I assure you will find multiple reasons to get excited. Listen to these experts and learn. The transfer of billions of dollars from Gold to Bitcoin is driving the prices. It as unstoppable as Tesla. It does not comply with normal market rational! But this is a new world.
Be careful though this is a fast moving market and it goes up and down so quickly. Best to take a long position with a sensible investment that you have no worries about and let it go! Then go and watch other easier to understand investments ;-)
Have a good week!
Cheers, Rich
Morning Headancer,
I agree with your points, just one point to note though ARB is on the main market, not AIM.
The company is increasing its capacity in February and last year they mined 2465 Bitcoin. As the value increases we could easily see an average over ÂŁ50k per Bitcoin. Strong revenue indeed.
Lots to be excited by here!
Cheers Rich.
I am astonished that this company with such a valuable therapeutic asset which is starting stage 2 as well as a billion dollar market has not got a huge following. If this company was better known the SP would be flying given its huge potential. Its incredible how many small Biotech companies in the UK right now have so much upside potential with truly pioneering and revolutionary products. With the experience of Stephanie Bewick could this be another joint listing on the NASDAQ? The interest in the NTCD-M3 project with the current cost to the US of $6.3 billion dollars per year would be hugely valuable. Lets hope the stage 3 trial required by the FDA is successful!
Interesting opportunities indeed.
Cheers, Rich